Sutro Biopharma, Inc. STRO

What this company does

Enabled through its XpressCF and XpressCF+ platforms, it has entered into multitarget, product-focused collaborations with pharmaceutical and biotechnology companies in the field of oncology, including an immunostimulatory ADC collaboration with Astellas Pharma Inc., a cytokine derivatives collaboration with Merck Sharp & Dohme Corp., a B Cell Maturation Antigen ADC collaboration with Celgene Corporation, and a MUC1-EGFR ADC collaboration with Merck KGaA. In 2022, it entered into a License and Collaboration Agreement with Astellas for the development of immunostimulatory ADCs for up to three biological targets. Its XpressCF and XpressCF+ platforms have also supported Vaxcyte, Inc., a company focused on the discovery and development of vaccines for the treatment and prophylaxis of infectious disease. It was incorporated under the laws of the State of Delaware in April 2003 under the name Fundamental Applied Biology, Inc., and subsequently changed its name to Sutro Biopharma, Inc.

Written from the business description in SUTRO BIOPHARMA, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 23 March 2026. Every sentence was checked against that document before publication.